Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy

Background: Spinal muscular atrophy (SMA) results from a loss-of-function mutation in the SMN1 gene. SMA patients suffer progressive motor disability, although no intellectual impairments have been described. Three drugs have been recently approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These drugs result in longer life expectancy for SMA type 1 (SMA1) patients. Objective: The objective of the study was to assess longitudinally the psychomotor development of patients with SMA1 treated after the symptom onset and of patients treated presymptomatically. Design: Longitudinal, monocentric, noninterventional, prospective study. Methods: Our study included 11 SMA1 patients and seven presymptomatic SMA patients. The SMA1 patients were treated with an approved drug beginning after onset of symptoms; treatment for the presymptomatic patients was begun before symptom onset. They were longitudinally evaluated between September 2018 and January 2022 using the Bayley Scales of Infant and Toddler Development™ – Third Edition. Results: At each time point, all patients treated presymptomatically scored above those treated postsymptomatically on the motor scale. The cognitive scores of six of the seven patients treated presymptomatically were average; one patient was in the low average range. In the 11 postsymptomatically treated patients, four scored either in the low average or the abnormal range on the cognitive scale, but a positive trend was observed during the follow-up. Conclusion: A significant proportion of patients treated postsymptomatically scored below average on cognitive and communicative scales, with most significant concerns raised about the age of 1 year. Our study indicates that intellectual development should be considered as an important outcome in treated SMA1 patients. Cognitive and communicative evaluations should be performed as part of standard of care, and guidance should be provided to parents for optimal stimulation.

[1]  R. Finkel,et al.  Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial , 2022, Nature Medicine.

[2]  R. Finkel,et al.  Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial , 2022, Nature Medicine.

[3]  M. Hiligsmann,et al.  Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening , 2022, Developmental medicine and child neurology.

[4]  C. Palermo,et al.  Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening , 2022, European Journal of Pediatrics.

[5]  C. Semenza,et al.  Cognitive profiles and clinical factors in type III spinal muscular atrophy: a preliminary study , 2022, Neuromuscular Disorders.

[6]  M. Hiligsmann,et al.  Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium , 2021, Scientific Reports.

[7]  M. Schroth,et al.  Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go , 2021, Neuromuscular Disorders.

[8]  E. Mercuri,et al.  Risdiplam in Type 1 Spinal Muscular Atrophy. , 2021, The New England journal of medicine.

[9]  G. Baranello,et al.  Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1 , 2021, Journal of Neurodevelopmental Disorders.

[10]  M. Hiligsmann,et al.  Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments , 2021, Orphanet Journal of Rare Diseases.

[11]  G. Baranello,et al.  Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review , 2021, Developmental medicine and child neurology.

[12]  D. Lulé,et al.  Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA) , 2021, Orphanet Journal of Rare Diseases.

[13]  K. Lidzba,et al.  Cognitive and academic profiles in children with cerebral palsy: a narrative review. , 2020, Annals of physical and rehabilitation medicine.

[14]  L. Servais,et al.  New treatments in spinal muscular atrophy: an overview of currently available data , 2020, Expert opinion on pharmacotherapy.

[15]  M. Hiligsmann,et al.  244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands , 2019, Neuromuscular Disorders.

[16]  L. Servais,et al.  Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives , 2019, Therapeutics and clinical risk management.

[17]  R. Finkel,et al.  Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study , 2019, Neuromuscular Disorders.

[18]  E. Tizzano,et al.  Severe brain involvement in 5q spinal muscular atrophy type 0 , 2019, Annals of neurology.

[19]  L. Servais,et al.  Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 , 2018, Neurology.

[20]  F. Aarsen,et al.  Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain , 2018, Developmental medicine and child neurology.

[21]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[22]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[23]  Hanns Lochmüller,et al.  Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review , 2017, Orphanet Journal of Rare Diseases.

[24]  Megan A. Lewis,et al.  A Review on Spinal Muscular Atrophy: Awareness, Knowledge, and Attitudes , 2016, Journal of Genetic Counseling.

[25]  Kyoko Tanaka,et al.  Bayley Scales of Infant and Toddler Development , 2015 .

[26]  W. Chung,et al.  Spectrum of Neuropathophysiology in Spinal Muscular Atrophy Type I , 2015, Journal of neuropathology and experimental neurology.

[27]  F. Aarsen,et al.  Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy , 2012, Neurology.

[28]  J. Ross,et al.  SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. , 2010, Human molecular genetics.

[29]  A. Meltzoff,et al.  Associations between media viewing and language development in children under age 2 years. , 2007, The Journal of pediatrics.

[30]  A. Gontard,et al.  Behavioural problems in children and adolescents with spinal muscular atrophy and their siblings , 2003, Developmental medicine and child neurology.

[31]  Jechil S. Sieratzki,et al.  Toddling into language: precocious language development in motor-impaired children with spinal muscular atrophy , 2002 .

[32]  A. Gontard,et al.  Intelligence and cognitive function in children and adolescents with spinal muscular atrophy , 2002, Neuromuscular Disorders.

[33]  J. Melki,et al.  The role of the SMN gene in proximal spinal muscular atrophy. , 1998, Human molecular genetics.

[34]  P. Patel,et al.  Brain atrophy in Werdnig‐Hoffmann disease , 1991, Acta neurologica Scandinavica.

[35]  Sato Yoko,et al.  Milestones for Communication Development in Japanese Children with Spinal Muscular Atrophy Type I , 2017 .